key: cord-0811478-y9r04i5k
authors: de Vries, Rory D; Rockx, Barry; Haagmans, Bart L; Herfst, Sander; Koopmans, Marion PG; de Swart, Rik L
title: Animal models of SARS-CoV-2 transmission
date: 2021-06-29
journal: Curr Opin Virol
DOI: 10.1016/j.coviro.2021.06.007
sha: dc0125de473db6f86e814fb89af74420ac5df0cb
doc_id: 811478
cord_uid: y9r04i5k

SARS-CoV-2 emerged in China as a zoonotic virus in December 2019. The virus proved to be human-to-human transmissible and its global spread resulted in the ongoing COVID-19 pandemic, associated with high morbidity and mortality. Vaccines were developed at an unprecedented speed and proved to be efficacious in preventing disease, but it remains to be determined if vaccines are able to interrupt transmission. Moreover, virus variants of concern continue to emerge that appear more transmissible and/or less sensitive to virus-specific immune responses. Here, we briefly review the role of animal models in assessing prophylactic and therapeutic options to interrupt SARS-CoV-2 transmission.

direct, indirect or close contact with infected individuals through contaminated secretions like saliva, respiratory droplets and aerosols. These droplets and aerosols can be expelled by coughing, sneezing, talking or singing and infect the subsequent host by reaching the respiratory tract or eyes [8] [9] [10] [11] [12] [13] [14] . Evidence for long-distance airborne transmission between humans is limited [15] . Despite consistent evidence that SARS-CoV-2 can survive on specific surfaces [16] [17] [18] [19] , evidence of fomite transmission between humans is also limited. In addition to respiratory transmission, viable SARS-CoV-2 has been demonstrated in urine [20] and stool specimens [21, 22] obtained from infected humans, but transmission via the fecal-oral route is thought to be of limited relevance in the spread of the virus among humans .

SARS-CoV-2 RNA can be detected by RT-PCR on nasopharyngeal swab material 1-3 days before symptom onset, with peak values around symptom onset, followed by a gradual decline over time [23] [24] [25] [26] [27] . Persistence of RNA for several weeks has been reported, especially in individuals with severe COVID- 19 [23,24,28,29] . However, detection of infectious virus is a better measure for transmissibility [30] . Shedding of infectious virus was initially not thought to occur for more than 8 days after symptom onset [24,31,32], but a recent study showed longer shedding of infectious virus in a selection of patients, which positively correlated with disease severity and viral load. In that study, infectious virus shedding became undetectable with the appearance of neutralizing antibodies in serum [30] . Comparative studies have shown that the relationship between detection of viral RNA and infectiousness differs between persons with mild and severe disease [33] . The level of shedding of viral RNA differs greatly among individuals, in part explaining the observed highly skewed patterns of transmission towards a limited proportion of human-to-human contacts [34] .

Transmission by individuals without symptoms was already suspected early in the pandemic.

Two transmission 'types' can be distinguished: transmission by asymptomatic (infected people J o u r n a l P r e -p r o o f who never develop symptoms) or by pre-symptomatic (infected people who have not yet developed symptoms) individuals. The true extent of asymptomatic infections is still unclear, but a recent systematic review and meta-analysis (that included several studies with limitations) estimated the proportion of truly asymptomatic cases to be 1 in 6 infections [35] . A study performed in close contacts of confirmed COVID-19 cases estimated the proportion to be 23% [36] . Both studies demonstrated transmission by asymptomatic individuals, albeit it to a lower extent compared to transmission by symptomatic patients. Pre-symptomatic transmission has often been demonstrated, and is in line with isolation of infectious virus as discussed above.

Although frequently demonstrated, the estimated rates of pre-symptomatic transmission vary considerably: from 6.4% up to 44% [25,37,38] . Clearly such parameters are not fixed and may differ for emerging variants with increased transmissibility and / or disease severity. Transmission by pre-or asymptomatic individuals (as described above for SARS-CoV-2) proved to be limited [46] . This strongly facilitated case-based surveillance, contract tracing and isolation J o u r n a l P r e -p r o o f measures. Although SARS-CoV was spread to multiple countries, the outbreak was fully contained by non-pharmaceutical interventions [47, 48] .

In 2012 another zoonotic coronavirus was identified as the causative agent of a cluster of severe respiratory tract disease patients in the Middle East and was named Middle East Respiratory Syndrome (MERS)-coronavirus [49] . Dromedary camels were identified as intermediate host [50, 51] and it is thought that the virus likely originated from bats (similar to SARS-CoV and SARS-CoV-2) [49, 52] . Although MERS-CoV rapidly spread globally [53], it is generally regarded less human-to-human transmissible than SARS-CoV or SARS-CoV-2, with an early estimate of an R0 below 1 in the general community and in households [54] . In healthcare settings human-to-human transmission has led to large outbreaks with higher R0, providing a warning sign for pandemic potential [55-57]. Continuous zoonotic events are being reported. The current consensus is that close and prolonged contact with an index case seems to be required for MERS-CoV transmission and adaptation would be required for efficient human-to-human transmission.

Strategies to contain the COVID-19 pandemic were initially limited to non-pharmaceutical . In addition, it remains to be determined what vaccination coverage will be reached eventually, given vaccine hesitancy and disparities in access. Therefore, for the months and years ahead, it is crucial to continue to explore potential additional countermeasures that inhibit SARS-CoV-2 transmission.

Animal models have been instrumental to gain insight into SARS-CoV, MERS-CoV and SARS-CoV-2 replication kinetics, shedding, pathogenesis and medical countermeasures, and ha ve been reviewed elsewhere [63-66]. These models include non-human primates (NHPs), cats, dromedary camels, ferrets, hamsters, rabbits and (transgenic) mice. Since coronaviruses emerge after zoonotic introduction, it is essential to study coronavirus transmission potential and evaluate transmission prevention by medical countermeasures. Animal models of transmission are therefore crucial. For SARS-CoV-2 specifically, this includes assessment of transmissibility of emerging variants, or transmission in the presence of vaccine-induced immunity. In this review, we provide a brief summary of the currently employed animal models to study different aspects of COVID-19, with a focus on transmission in combination with therapeutics that could interrupt transmission.

Transmission studies in animal models are relatively scarce. Natural SARS-CoV-2 transmission in animals has been described in companion animals (e.g., cats and dogs) and on mink farms.

Experimental animal transmission models remain limited to the cat, ferret and hamster model. Table 1 .

Naturally occurring human-to-animal transmission was already reported during the SARS-CoV [71] was observed, but in most cases infected animals remained asymptomatic [72] . This remains to be determined for emerging variants [73] . Experimental infections confirmed susceptibility of cats, but dogs proved poorly susceptible [74, 75] .

Cats were also evaluated as an animal model for SARS-CoV-2 transmission. A first study assessed airborne transmission among cats housed in adjacent cages (also allowing for respiratory droplet transmission) and demonstrated that experimental transmission is feasible, although this remained limited to infection of 1 out of 3 sentinel animals [75] . Direct contact transmission in cats was more robust, showing infection of all sentine l animals in several separate small studies [74, 76, 77] .

Large outbreaks of SARS-CoV-2 infection have been reported on mink (Neovison vison) farms in the Netherlands, Spain, Italy, Sweden, Greece, the US and Denmark, initiated by a human-tomink transmission [78] . Circulation and spread initially went unnoticed as mustelids usually develop asymptomatic or mild disease, and transmission on some farms was only confirmed J o u r n a l P r e -p r o o f after serological surveys. However, upper and lower respiratory tract involvement has been described [79, 80] . Transmission on mink farms was rapid and widespread after initial introduction. Once introduced, it has proven difficult to stop transmission on a farm, and ongoing transmission between farms was described [81] . Large-scale culling of mink was initiated when it was observed that ongoing SARS-CoV-2 transmission led to an accumulation of mutations in the S protein, and that these viruses could spill back from mink farms into the community in 

Ferrets (Mustela putorius furo) are an invaluable model to study the pathogenicity and transmission of respiratory viruses [85] . In SARS-CoV-2 infection studies, it was shown that ferrets rarely develop clinical signs of disease. Weight loss is not observed, some studies report a slight and transient fever. Additionally, mild respiratory symptoms ( e.g., nasal discharge) and mild haematological changes (e.g., lymphopenia) have occasionally been reported [75, [86] [87] [88] [89] .

However, although clinical symptoms are absent or mild, there is substant ial shedding of SARS-CoV-2 observed in the respiratory tract, starting at day 2 and sometimes still detectable by RT -PCR two weeks post inoculation [87, 90, 91] . Since ferrets develop no or relatively mild disease and histopathological changes, combined with RT-PCR detectable viral loads and shedding from the respiratory tract, ferrets are regarded an optimal model for asymptomatic or mild disease in humans and are often used in transmission studies [92] . Recently, it was shown that aged ferret (>3 years old) have higher viral loads, longer shedding and more severe lung J o u r n a l P r e -p r o o f load in the upper respiratory tract of ferrets and prevented transmission to untreated contact animals that were exposed 30 hrs after inoculation of donors [95] .

Molecular docking studies on the binding between Ace2 and the S protein initially suggested that the Syrian golden hamster (Mesocricetus auratus) is a suitable small animal model for SARS-CoV-2 pathogenesis studies [96, 97] . Indeed, upon intranasal challenge hamsters develop acute but transient respiratory distress, peaking at 4-5 days post inoculation, and lose weight, followed by an eventual recovery [96] [97] [98] . SARS-CoV-2 infection of hamsters is associated with high viral loads and prolonged detection of viral genomes in oral swabs and nasal washes by RT-PCR. Hamsters additionally show clear histopathological lesions [96, 98, 99] . Upon comparison of the course of SARS-CoV-2 infection in young and aged hamsters, it was found that replication kinetics are similar but aged hamst ers exhibit more pronounced weight loss, combined with more histopathological lung damage [100] . Because hamsters recapitulate (part of) COVID-19 disease as observed in humans and they are a relatively easy to handle, hamsters are a valuable model to study severe COVID-19 in humans.

Furthermore, hamsters can be used to screen antiviral agents in a disease model [101] . Finally, hamsters have been used in adoptive transfer and vaccination challenge studies [102, 103] .

Although viral RNA can persist in the hamster respiratory tract, infectious virus can be detected only for a short period after intranasal inoculation, leaving a potentially small window for transmission. However, transmission of SARS-CoV-2 to naive animals that were co-housed with infected animals in a direct contact setup is robust [96, 97, 104] . It was determined that the minimal amount of contact time between infected and naive hamsters required for efficient transmission is 4 hours [105] or less [97] . In addition, despite the prolonged detection of viral RNA in nasal washes and throat swabs for over 2 weeks, transmission only occurs during the J o u r n a l P r e -p r o o f first 6 days post inoculation [97] . Aerosol transmission models for hamsters have also been developed, are robust, and more efficient than fomite transmission [97, 104] . Interestingly, hamsters infected through direct contact transmission develop no or only limited weight loss, in contrast to directly inoculated animals.

Prior exposure of hamsters to SARS-CoV-2 resulted in protection from re-infection, with significantly reduced virus replication in the upper respiratory tract [106] . Virus was not transmitted to naive contact animals, suggesting that natural immunity to SARS-CoV-2 can prevent transmission. However, to date, immunity induced by most vaccine candidates or passive transfer of neutralizing antibodies can only effectively protect against respiratory disease in the lower respiratory tract, but not in the nose [96, 98, 105, 107] . The hamster model has also been used to evaluate the efficacy of non-medical intervention strategies, such as surgical masks. In a single study, SARS-CoV-2 could be transmitted by respiratory droplets or airborne droplet nuclei which could be reduced by a surgical mask partition between infected and naive hamsters [108] .

Finally, most hamster transmission studies have focused on respiratory transmission; however, other routes of transmission may occur. Especially in direct contact set-ups, concerns of fecaloral transmission have been raised given that hamsters can be infected via the oral route and SARS-CoV-2 shedding has been detected in feces of experimentally infected animals [109] .

In conclusion, SARS-CoV-2 transmission and transmission intervention studies in animal models remain scarce and have mostly been performed with the classical variant of SARS-CoV-2. Zhou et al addressed the transmissibility of the predominant circulating variant (D614G) [110] in the hamster and ferret model, in a pairwise competition setup in 6 animal pairings, and J o u r n a l P r e -p r o o f observed increased transmission of the variant [111] . Future studies will need to address differences in transmissibility of novel emerging variants of concern, for which epidemiological studies have demonstrated potential increased transmissibility in humans. Another aspect that future transmission studies will need to take into account is the age of animals. COVID -19 is most severe in the elderly (with underlying co-morbidities) [3] , but transmission studies so far do not take age into account. In pathogenesis studies it was shown that SARS-CoV-2 causes more severe disease in aged hamsters, ferrets, and non-human primates [112, 113] . Similar observations were reported for experimental infections with SARS-CoV [114] . The influence of gender of experimental animals in transmission studies is still unknown.

Several potential pitfalls should be taken into account when performing these studies: (1) adequate production and characterization of non-adapted viral stocks with a representative viral sequence [115] , (2) Only few studies have assessed prevention of SARS-CoV-2 transmission by antibodies or antiviral compounds. When studying the effectiveness of candidate intervention strategies, this should be studied both at level of the infected host (therapeutic efficacy, e.g., nucleoside analogues) and at the level of the recipient (prophylactic efficacy, e.g., fusion inhibitory J o u r n a l P r e -p r o o f combination therapy using antiviral compounds with different working mechanisms.

In conclusion, mitigation of SARS-CoV-2 transmission will be crucial to contain the ongoing COVID-19 pandemic. This will likely require a combination of non-pharmaceutical interventions, increased vaccination coverage and potentially antivirals that reduce virus loads or prevent virus entry. Transmission studies in animal models may support pre-clinical identification of promising intervention strategies for further clinical testing.

Declarations of interest: none. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. 

Coronaviridae Study Group of the International Committee on Taxonomy of V: The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

The proximal origin of SARS-CoV

A new coronavirus associated with human respiratory disease in China

A Genomic Perspective on the Origin and Emergence of SARS-CoV-2

Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins

Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins

Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses

This study describes the high diversity of coronaviruses in South-East Asian bat species, including close relatives of SARS-CoV and SARS-CoV-2

Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient

Prolonged Infectivity of SARS-CoV-2 in Fomites. Emerg Infect Dis 2020

Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

* initial comparison of potential for aerosol and fomite transmission of SARS -CoV and SARS-CoV-2

Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Viral loads in clinical specimens and SARS manifestations

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Seroprevalence of SARS coronavirus antibody in household contacts

Transmission dynamics and control of severe acute respiratory syndrome

Advisors of Expert SgoHA: Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS)

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation

A household case evidences shorter shedding of SARS-CoV-2 in naturally infected cats compared to their human owners

Myocarditis in naturally infected pets with the British variant of COVID-19

SARS-CoV-2 infection, disease and transmission in domestic cats

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2

Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats

Transmission of SARS-CoV-2 in Domestic Cats

SARS-CoV-2 and the human-animal interface: outbreaks on mink farms

Clinical and Pathological Findings in SARS-CoV-2 Disease Outbreaks in Farmed Mink (Neovison vison)

SARS-CoV-2 infection in farmed minks, the Netherlands

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans

SARS-CoV-2 in Danish Mink Farms: Course of the Epidemic and a Descriptive Analysis of the Outbreaks in 2020. Animals (Basel) 2021

SARS-CoV-2 Transmission between Mink (Neovison vison) and Humans, Denmark. Emerg Infect Dis 2021

Corona's new coat: SARS-CoV-2 in Danish minks and implications for travel medicine

Ferret models of viral pathogenesis

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Infection and Rapid Transmission of SARS-CoV-2 in Ferrets

Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity

SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study

Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets

This study shows that intranasal administration of a fusion inhibitory lipopeptide can prevent direct contact transmission in ferrets

SARS-CoV-2 is transmitted via contact and via the air between ferrets

Intranasal Infection of Ferrets with SARS-CoV-2 as a Model for Asymptomatic Human Infection

Age-dependent pathogenic characteristics of SARS-CoV-2 infection in ferrets

SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets over more than one meter distance

** This study demonstrates that SARS-CoV and SARS-CoV

Therapeutically administered ribonucleoside analogue MK

EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

This study demonstrates that treatment of SARS-CoV-2-infected ferrets with an oral drug can prevent onward transmission to susceptible animals

Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

** Demonstration of infection, disease and transmission of SARS-CoV-2 in hamsters

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters

Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

A single-dose liveattenuated YF17D-vectored SARS-CoV-2 vaccine candidate

SARS-CoV-2 disease severity and transmission efficiency is increased for airborne but not fomite exposure in Syrian hamsters

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques

SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Surgical Mask Partition Reduces the Risk of Noncontact Transmission in a Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19)

Oral SARS-CoV-2 Inoculation Establishes Subclinical Respiratory Infection with Virus Shedding in Golden Syrian Hamsters

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

SARS-CoV-2 spike D614G change enhances replication and transmission

Acute Respiratory Distress in Aged, SARS-CoV-2-Infected African Green Monkeys but Not Rhesus Macaques

Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets

Exacerbated innate host response to SARS-CoV in aged non-human primates

Supporting pandemic response using genomics and bioinformatics: A case study on the emergent SARS-CoV-2 outbreak

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice